Evidence map›Paper›PMID 20692814›Full record

SynthesisSchizophrenia research2010

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.

Christine Rummel-Kluge, Katja Komossa, Sandra Schwarz, Heike Hunger, Franziska Schmid, Claudia Asenjo Lobos, Werner Kissling, John M Davis, Stefan Leucht

2 registry-linked trialsOpen access · greenAbstract readComparative StudyMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Schizophrenia research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 267 papers, 30 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
267citing papers in PubMed, 30 pooled it
28.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05663749 phase4completedstarted 2022, after this paper: background citation

Efficacy and Safety of Add-on Topiramate vs Metformin on Cardio-Metabolic Profile in Patients With Schizophrenia on Atypical Antipsychotics With Metabolic Syndrome: a Randomized Controlled Trial

Ran2022Enrolled60Registered outcomes5Posted comparisons0ConditionsMetabolic Syndrome, SchizophreniaArmsMetformin, topiramate
PMID 20233913PMID 18082302PMID 31009043PMID 17873679PMID 3616518PMID 33454933PMID 29557263PMID 27716110PMID 26781921PMID 26280837PMID 23694688PMID 21284696other papers from this trial
Open the trial in the graph
NCT07770282 phase3not yet recruitingstarted 2026, after this paper: background citation

Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome: A Multicentre, Double-Blind, Randomised Controlled Trial (ESCaMS Trial)

Ran2026Enrolled600Registered outcomes10Posted comparisons0ConditionsAntipsychotic-induced Weight Gain, Cardiovascular Risk, Insulin Resistance, Metabolic SyndromeArmsPlacebo + TAU, Semaglutide + TAU
PMID 10553730PMID 24763306PMID 22207632PMID 18466668PMID 17909124other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

267 citing papers in PubMed, 30 syntheses or guidelines pooled it, 672 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Bayesian Meta-analysis of Multiple Continuous Treatments with Individual Participant-Level Data: An Application to Antipsychotic Drugs.Medical decision making : an international journal of the Society for Medical Decision Making · 2019
    Pooled it
  19. Pooled it
  20. Pooled it

207 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Christine Rummel-KlugeKlinik und Poliklinik für Psychiatrie und Psychotherapie der Technischen Universität München, Klinikum rechts der Isar, Möhlstr. 26, 81675 München, Germany. christine.rummel@lrz.tum.de
Katja Komossa
Sandra Schwarz
Heike Hunger
Franziska Schmid
Claudia Asenjo Lobos
Werner Kissling
John M Davis
Stefan Leucht
München Klinik · DEKlinikum rechts der Isar · DEKlinik und Poliklinik für Psychiatrie und Psychotherapie · DEUniversidad de La Frontera · CLUniversity of Illinois Chicago · US

Funding

CORE--RESEARCH NETWORK DEVELOPMENT COREP30MH068580 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI CARPENTER, WILLIAM T. · 2003 to 2007
$7.9M
NIMH NIH HHS 1 P01MH68580-01NIMH NIH HHS MH-68580NIMH NIH HHS P30 MH068580
6 · The paper itself

Abstract

objectiveThe metabolic side effects of second-generation antipsychotics (SGA) are serious and have not been compared head to head in a meta-analysis. We conducted a meta-analysis of studies comparing the metabolic side effects of the following SGAs head-to-head: amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone, zotepine.

methodWe searched the register of the Cochrane schizophrenia group (last search May 2007), supplemented by MEDLINE and EMBASE (last search January 2009) for randomized, blinded studies comparing the above mentioned SGA in the treatment of schizophrenia or related disorders. At least three reviewers extracted the data independently. The primary outcome was weight change. We also assessed changes of cholesterol and glucose. The results were combined in a meta-analysis.

resultsWe included 48 studies with 105 relevant arms. Olanzapine produced more weight gain than all other second-generation antipsychotics except for clozapine where no difference was found. Clozapine produced more weight gain than risperidone, risperidone more than amisulpride, and sertindole more than risperidone. Olanzapine produced more cholesterol increase than aripiprazole, risperidone and ziprasidone. (No differences with amisulpride, clozapine and quetiapine were found). Quetiapine produced more cholesterol increase than risperidone and ziprasidone. Olanzapine produced more increase in glucose than amisulpride, aripiprazole, quetiapine, risperidone and ziprasidone; no difference was found with clozapine.

conclusionsSome SGAs lead to substantially more metabolic side effects than other SGAs. When choosing an SGA for an individual patient these side effects with their potential cause of secondary diseases must be weighed against efficacy and characteristics of the individual patient.

Indexed as

AmisulprideAntipsychotic AgentsAripiprazoleBenzodiazepinesBlood GlucoseCholesterolClinical Trials as TopicClozapineDibenzothiazepinesHumansImidazolesIndolesOlanzapinePiperazinesQuetiapine FumarateQuinolonesAmisulprideAntipsychotic AgentsAripiprazoleBenzodiazepinesBlood GlucoseCholesterolClozapineDibenzothiazepinesImidazolesIndolesOlanzapinePiperazinesQuetiapine FumarateQuinolonesRisperidonesertindoleSulpirideThiazolesziprasidone

Identifiers

PMID20692814
PMCPMC2957510
OpenAlexW2061525750

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.